RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hikma Pharmaceuticals Stock

Hikma Pharmaceuticals ROCE 2025

Hikma Pharmaceuticals ROCE

0.27

Ticker

HIK.L

ISIN

GB00B0LCW083

WKN

A0HG69

In 2025, Hikma Pharmaceuticals's return on capital employed (ROCE) was 0.27, a -3.78% increase from the 0.28 ROCE in the previous year.

Hikma Pharmaceuticals Aktienanalyse

What does Hikma Pharmaceuticals do?

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Hikma Pharmaceuticals's Return on Capital Employed (ROCE)

Hikma Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Hikma Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Hikma Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Hikma Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Hikma Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Hikma Pharmaceuticals this year?

The ROCE of Hikma Pharmaceuticals is 0.27 undefined this year.

How has the ROCE (Return on Capital Employed) of Hikma Pharmaceuticals developed compared to the previous year?

The ROCE of Hikma Pharmaceuticals has increased by -3.78% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Hikma Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Hikma Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Hikma Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Hikma Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Hikma Pharmaceuticals impact the company?

An increase in the ROCE of Hikma Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Hikma Pharmaceuticals affect the company?

A decrease in ROCE of Hikma Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Hikma Pharmaceuticals?

Some factors that can affect Hikma Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Hikma Pharmaceuticals so important for investors?

The ROCE of Hikma Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Hikma Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Hikma Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.93 USD . This corresponds to a dividend yield of about 3.51 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.99 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 3.51 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, September, September, April.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.99 USD are expected. This corresponds to a dividend yield of 3.71 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 5/1/2025 amounting to 0.372 USD, you needed to have the stock in your portfolio before the ex-date on 3/20/2025.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/1/2025.

What was the dividend of Hikma Pharmaceuticals in the year 2024?

In the year 2024, Hikma Pharmaceuticals distributed 0.494 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hikma Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.